Core Viewpoint - The stock price of Prise has shown significant fluctuations, with a year-to-date increase of 74.65% but a recent decline of 1.20% over the last five trading days [2]. Company Overview - Prise (Shanghai) Pharmaceutical Technology Development Co., Ltd. was established on February 22, 2013, and went public on May 17, 2022. The company is located at 500 Guangdong Road, 23rd Floor, World Trade Building, Huangpu District, Shanghai [2]. - The main business involves technology development, transfer, consulting, and services in the pharmaceutical field, with 100% of its revenue coming from services [2]. - The company belongs to the pharmaceutical and biotechnology sector, specifically in medical services and medical research outsourcing [2]. Financial Performance - For the first half of 2025, Prise reported a revenue of 390 million yuan, a year-on-year decrease of 1.08%, and a net profit attributable to shareholders of 54.16 million yuan, down 1.40% year-on-year [2]. - Since its A-share listing, Prise has distributed a total of 40.77 million yuan in dividends [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for Prise was 8,571, a decrease of 1.88% from the previous period, with an average of 8,787 circulating shares per person, an increase of 1.91% [2]. - The top ten circulating shareholders include Tianhong Medical Health A, which holds 1.4287 million shares, a decrease of 17,600 shares from the previous period, and Rongtong Health Industry Flexible Allocation Mixed A/B, which holds 1 million shares, an increase of 100,000 shares [3].

Group 1 - The company announced that it will hold a staff representative meeting on September 26, 2025 [2] - During the meeting, the staff representatives voted to elect Gu Shengnan as the employee representative director for the company's third board of directors [2]

关于选举公司第三届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"）根据《中华 人民共和国公司法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所 上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律法规、规范 性文件及《公司章程》的有关规定，公司董事会设职工代表董事一名。 公司于 2025 年 9 月 26 日召开职工代表大会，经全体与会职工代表审议，通 过投票表决，同意选举顾胜男女士为公司第三届董事会职工代表董事（简历详见 附件）。顾胜男女士将与公司现任的 8 位董事共同组成公司第三届董事会，任期 自本次职工代表大会审议通过之日起至第三届董事会任期届满之日止。 顾胜男女士当选公司职工代表董事后，公司第三届董事会兼任高级管理人员 以及由职工代表担任的董事人数未超过公司董事总数的二分之一，符合相关法律 法规及《公司章程》的规定。 证券代码：301257 证券简称：普蕊斯 公告编号：2025-060 普蕊斯（上海）医药科技开发股份有限公司 特此公告。 普蕊斯（上海） ...

特别提示： 1、本次会议采取现场表决与网络投票相结合的方式。 2、本次股东大会不存在否决提案的情况。 3、本次股东大会不涉及变更以往股东大会已通过的决议。 4、本次股东大会表决的提案中，提案 5.00 以提案 1.00 审议通过为前提条件。 证券代码：301257 证券简称：普蕊斯 公告编号：2025-059 普蕊斯（上海）医药科技开发股份有限公司 2025 年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、会议召开和出席情况 1、召开时间： （1）现场会议召开时间：2025 年 9 月 26 日（星期五）14:45 （2）网络投票时间：通过深交所交易系统进行网络投票的具体时间为：2025 年 9 月 26 日 9:15-9:25，9:30-11:30 和 13:00-15:00；通过深交所互联网投票系统 投票的具体时间为 2025 年 9 月 26 日 9:15-15:00 期间的任意时间。 2、召开地点：上海市黄浦区广东路 500 号世界贸易大厦 23 楼大会议室 3、召开方式：现场表决与网络投票相结合的方式 4、召集人：普 ...

上海市黄浦区中山东二路 600 号 BFC 外滩金融中心 S2 栋 23 层 电话：021-23122000 传真：021-23122100 邮编：200010 北京国枫（上海）律师事务所 关于普蕊斯（上海）医药科技开发股份有限公司 2025 年第三次临时股东大会的法律意见书 对本法律意见书的出具，本所律师特作如下声明： 1. 本所律师仅就本次会议的召集与召开程序、召集人和出席现场会议人员资格、 会议表决程序及表决结果的合法性发表意见，不对本次会议所审议的议案内容及该等 议案所表述的事实或数据的真实性、准确性和完整性发表意见； 2. 本所律师无法对网络投票过程进行见证，参与本次会议网络投票的股东资格、 网络投票结果均由相应的证券交易所交易系统和互联网投票系统予以认证； 3. 本所律师已经按照《股东会规则》的要求，对贵公司本次会议所涉及的相关 事项进行了必要的核查和验证，所发表的结论性意见合法、准确，不存在虚假记载、 误导性陈述或者重大遗漏； 4. 本法律意见书仅供贵公司本次会议之目的使用，不得用作任何其他用途。本 所律师同意将本法律意见书随贵公司本次会议决议一起予以公告。 本所律师根据《公司法》《证券法》《股 ...

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [2] Core Insights - The CXO industry is experiencing a recovery in market conditions, driven by improvements in supply-demand dynamics and a rebound in financing activities for innovative drugs [3][4] - The CDMO sector continues to show high growth potential, with leading companies improving their performance and expanding into emerging markets [5][6] - The CRO sector is approaching a turning point, with signs of demand recovery and improved order conditions [6][7] Summary by Sections CXO Industry Overview - The CXO industry operates on a "water seller" business model, closely tied to the financing of the biopharmaceutical sector. In the first eight months of 2025, overseas innovative drug financing reached $22.6 billion, a year-on-year decline of approximately 36%, while domestic innovative drug financing amounted to $7.75 billion, a year-on-year increase of about 89% [3][31] - The leading companies in the CXO sector are expected to enter an expansion phase as demand recovers, while smaller companies may face increased competition and exit the market [4][44] CDMO Sector - CDMO leading companies have begun to see marginal improvements in performance since Q4 2024, attributed to high overseas revenue and a unique business model that supports project pipeline growth [5][46] - The order situation for CDMO companies has improved significantly, with notable increases in backlogged orders for major players like WuXi AppTec and WuXi Biologics [49][50] - The CDMO business model is characterized by strong customer retention and project scalability, allowing for sustained growth despite challenges in new project signings [52] CRO Sector - The CRO sector is witnessing a divergence in performance among leading companies, with some starting to recover. The overall order situation has shown improvement, indicating a potential demand revival [6][22] - The price increase of experimental monkeys suggests a forthcoming recovery in preclinical CRO demand, highlighting the importance of resource availability for leading CRO companies [6][24] - The integration of AI in drug development processes is expected to enhance efficiency and reduce costs, with many domestic CRO leaders already adopting AI technologies [7][18] Recommended Companies - The report suggests focusing on key players in the CXO sector, including WuXi AppTec, WuXi Biologics, WuXi AppTec, and others, which are positioned well for growth based on their business characteristics and market trends [8][10]

Core Insights - The total margin financing balance of the ChiNext market reached 5147.54 billion yuan as of September 25, 2025, marking an increase of 26.17 billion yuan from the previous trading day, with the financing balance alone at 5130.85 billion yuan, up by 26.32 billion yuan, continuing a four-day upward trend with a cumulative increase of 94.53 billion yuan [1][2]. Margin Financing Changes - The number of stocks with increased financing balances during this period was 443, with 50 stocks seeing increases exceeding 20%. The stock with the highest increase was Green Island Wind, with a financing balance of 1.18 billion yuan and an increase of 127.26%. Other notable increases were seen in Changchuan Technology and Hongfuhan, with increases of 109.62% and 69.68%, respectively [2][3]. - Conversely, 502 stocks experienced a decrease in financing balances, with 62 stocks declining by more than 10%. The largest decrease was recorded by Puris, with a financing balance of 631.16 million yuan, down by 46.74% [2][3]. Sector Performance - Among the stocks with financing balance increases exceeding 20%, the majority were concentrated in the electronics, machinery equipment, and power equipment sectors, with 19, 7, and 5 stocks respectively [4]. - The average increase in stock prices for those with financing balance increases over 20% was 8.41%, outperforming the ChiNext index. The top performers included Changchuan Technology, Weiteou, and Guomai Culture, with increases of 47.82%, 34.05%, and 31.26%, respectively [4]. Notable Companies - The company with the highest financing balance increase was Ningde Times, with a latest balance of 16.277 billion yuan, increasing by 2.332 billion yuan. Other companies with significant increases included Xinyi Sheng and Zhongji Xuchuang, with increases of 1.829 billion yuan and 1.588 billion yuan, respectively [5]. - Companies with the largest decreases in financing balances included Shenghong Technology, Dongfang Fortune, and Tonghuashun, with decreases of 1.462 billion yuan, 863 million yuan, and 474 million yuan, respectively [5].

Core Insights - The latest financing balance of the ChiNext market is 506.12 billion yuan, with a week-on-week increase of 2.49 billion yuan, indicating a positive trend in financing activities [1] - On September 22, the ChiNext index rose by 0.55%, with a total margin balance of 507.76 billion yuan, reflecting an increase of 2.52 billion yuan from the previous trading day [1] - A total of 501 stocks in the ChiNext saw an increase in financing balance, with 34 stocks experiencing a growth rate exceeding 10% [1] Financing Balance Growth - The stock with the highest increase in financing balance is Tongyou Technology, with a latest financing balance of 495.39 million yuan, showing a week-on-week increase of 46.50% and a price increase of 5.87% [3] - Other notable stocks with significant financing balance growth include Shen Shui Institute and Green Island Wind, with increases of 35.92% and 33.75% respectively [3] - Among the stocks with over 10% increase in financing balance, the average price increase on the same day was 5.02%, with notable performers including Guomai Culture, Tianyi Horse, and Lihexing, which rose by 19.99%, 15.38%, and 14.62% respectively [1][3] Financing Balance Decline - A total of 443 stocks experienced a decline in financing balance, with 13 stocks showing a decrease of over 10% [4] - The stock with the largest decline in financing balance is Puris, with a latest financing balance of 80.92 million yuan, reflecting a decrease of 31.71% [5] - Other stocks with significant declines include Kailong High-Tech and Weili Transmission, with decreases of 21.44% and 16.41% respectively [5]

证券代码：301257 证券简称：普蕊斯 公告编号：2025-058 普蕊斯（上海）医药科技开发股份有限公司 关于召开 2025 年第三次临时股东大会提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》和《公司章程》的有关规定，经普蕊斯（上 海）医药科技开发股份有限公司（以下简称"公司"）第三届董事会第十五次会议 审议通过，拟于 2025 年 9 月 26 日（星期五）召开公司 2025 年第三次临时股东 大会（以下简称"股东大会"），现将本次股东大会有关事项提示如下： 一、召开会议的基本情况 1、股东大会届次：2025 年第三次临时股东大会 2、股东大会的召集人：公司董事会 3、会议召开的合法性、合规性：本次股东大会的召开符合有关法律、行政 法规、部门规章、规范性文件、深圳证券交易所（以下简称"深交所"）业务规则 和《公司章程》等的规定。 4、会议召开的日期、时间： （1）现场会议时间：2025 年 9 月 26 日（星期五）14：45； （2）网络投票时间：通过深交所交易系统进行网络投票的具体时间为 2025 年 9 月 ...

Group 1 - The A-share market's weight-loss drug concept stocks have weakened significantly, with BoRui Pharmaceutical dropping nearly 10% [1] - Zhongsheng Pharmaceutical experienced a decline of over 8% [1] - ProLogis and ProPace both fell by more than 3% [1]